Genmab
Manufacturing · Denmark · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Kalvebod Brygge 43, København V, Capital...Phone Number
+45 70202728Website
www.genmab.comRevenue
$3.3 BillionStock Symbol
GMABIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
6
1
2
1
2
1
About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and ToRead more
Genmab Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genmab your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Genmab recently announced quarterly report
Genmab, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Genmab is spiking on competitors!
Click to see if Genmab had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Genmab
Check if Genmab has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Genmab launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Genmab has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Genmab is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Genmab is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Genmab.
Genmab Tech Stack
A closer look at the technologies used by Genmab
See more technologies
Most Recent Scoops
Person-Based
Medical Research
Open Position
Open Position
Open Position
Open Position
Genmab News & Media
Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks on our list. TheFly reported on July 2 that H.C. Wainwright analyst Raghuram Selvaraju increased the price target on GMAB to $40 from $38 while reaffirming a Buy rating on the shares. […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genmab
Sign Up For FreeTo access detailed company insights
Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody... Read More
